Cargando…

The natural history of sporadic non‐ampullary duodenal epithelial tumors: Can we wait and see?

OBJECTIVES: The natural history of sporadic non‐ampullary duodenal epithelial tumors (SNADETs) is poorly documented. The aim of this study was to evaluate the history of SNADETs in patients where immediate resection could not be performed. METHODS: This is a single‐center retrospective study of 86 c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakaguchi, Yoshiki, Tsuji, Yosuke, Ushiku, Tetsuo, Kubota, Dai, Sato, Junichi, Obata, Miho, Cho, Rina, Nagao, Sayaka, Sakuma, Nobuyuki, Tamura, Naoki, Miura, Yuko, Fukagawa, Kazushi, Ohki, Daisuke, Mizutani, Hiroya, Takeuchi, Chihiro, Takahashi, Yu, Minatsuki, Chihiro, Niimi, Keiko, Yamamichi, Nobutake, Koike, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828177/
https://www.ncbi.nlm.nih.gov/pubmed/35310152
http://dx.doi.org/10.1002/deo2.9
Descripción
Sumario:OBJECTIVES: The natural history of sporadic non‐ampullary duodenal epithelial tumors (SNADETs) is poorly documented. The aim of this study was to evaluate the history of SNADETs in patients where immediate resection could not be performed. METHODS: This is a single‐center retrospective study of 86 consecutive cases of SNADETs who did not undergo immediate resection and were followed‐up with upper gastrointestinal endoscopy for more than 6 months. RESULTS: During a follow‐up period of 36.8 (6.0–613.0) months, macroscopic progression was admitted in eight (9.3%). Of these, the final histology in four was adenocarcinoma, and three cases demonstrated submucosal invasion. Rates of macroscopic progression at 150 months after detection were 11.1%, 16.7%, and 30.0% for SNADETs <5 mm, <10 mm, and ≥10 mm, respectively. CONCLUSION: The overall risk of SNADETs progressing to invasive cancer is low. However, changes in macroscopic size or shape of SNADETs signify a high risk of progression to invasive cancer.